Ipsen and PeptiMimesis announce oncology research partnership
pharmafile | March 9, 2016 | News story | Research and Development |Â Â INSERM, PeptiMimesis, ipsen, peptidesÂ
Specialist pharma company Ipsen is partnering with French start-up PeptiMimesis to develop and market of novel therapeutic peptides in oncology.
Ipsen aims to combine its expertise in peptide design and development with PeptiMimesis’ knowledge in the identification of transmembrane peptides and intracellular signalling. The target receptor is involved in different phases of cancer development, including angiogenesis, immune tolerance and proliferation.
Under the terms of the agreement, Ipsen and PeptiMimesis will work closely together to move the project forward towards clinical development. PeptiMimesis will receive financial support from Ipsen for the research phases, as well as milestone payments associated with the program. If the option is exercised, Ipsen could make further potential payments to PeptiMimesis at development, regulatory and commercial milestones, as well as royalty payments on worldwide annual net sales.
PeptiMimesis is a spin-off project from INSERM (French National Institute of Health and Medical Research) and Strasbourg University, funded by SATT Conectus Alsace. The company was created in October 2015.
Pascal Neuville, chief executive officer of Domain Therapeutics, co-founding company of PeptiMimesis and chairman of PeptiMimesis, comments: “PeptiMimesis is extremely proud that its innovative approach is recognised by Ipsen, a prominent partner in therapeutic peptides. We are convinced that this initial collaboration will pave the way for a series of partnerships, given the tremendous possibilities of targeting transmembrane receptors.
“This partnership is the result of more than 15 years of research that reached the validation stage thanks to the support of SATT Conectus. Work on the project will now continue in close co-operation between my laboratory, PeptiMimesis, and Ipsen,” adds Dominique Bagnard, PeptiMimesis scientific founder.
Claude Bertrand, executive vice president, research & development and chief scientific officer of Ipsen, says: “We have been working with Dominique Bagnard’s team since 2014 to assess the potential of transmembrane targeting of a specific receptor identified as involved in cancer development. We are delighted to continue our involvement with the young start-up PeptiMimesis, to combine our strengths and expertise to identify and develop new treatments for cancer patients. The project aligns perfectly with our research strategy and extends our expertise in peptides.”
It has been a busy start to March for Ipsen, which last week announced it had signed a licensing agreement with Exelixis for an experimental cancer drug. The deal was reported to potentially be worth as much as $855 million, based on the drug hitting development and regulatory milestones.
Joel Levy
Related Content
MetP Pharma releases positive data on intranasal semaglutide administration
MetP Pharma has released new data highlighting the advantages of its MetP technology in delivering …
Ipsen’s Iqirvo approved for use in NHS Scotland to treat rare liver disease
The Scottish Medicines Consortium (SMC) has accepted the use of Ipsen’s Iqirvo (elafibranor) in NHS …
Amferia closes €1,2 million investment to combat resistant bacterial infections
Swedish medtech company Amferia announces the successful completion of its latest investment round, boosting its …
